Loading company…
Riskpilot
← Back to search
Sign in
Get full access
GENE-USE.CO AS
AS
Active
Org 926188429
Vennersborgveien 12D, 0281 Oslo
Support activities for animal production · NACE 0162
Est. 2020
0 employees
www.gene-use.co
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2022
NOK 4K
EBITDA margin
-8245.8%
-46% vs 2021
Equity ratio
-1405.7%
Financial strength
Net profit 2022
NOK -349K
-114% vs 2021
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2020
0M
0%
2021
0M
0%
2022
Key figures
Annual report 2022
Revenue
NOK 4K
—
EBITDA
NOK -303K
-46%
Net profit
NOK -349K
-114%
Total assets
NOK 15K
-74%
Equity
NOK -204K
-657%
Employees
0
—
Company information
Legal name
GENE-USE.CO AS
Org number
926188429
Legal form
Aksjeselskap
NACE code
0162 · Support activities for animal production
Founded
28. desember 2020
Share capital
NOK 38 358
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Company purpose
Kunstig intelligens brukt for å forutse kvaliteten på fullblodshester (galopphester) basert på stamtavler.
Contact
Address
Vennersborgveien 12D, 0281 Oslo
Website
www.gene-use.co
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Support activities for animal production
Companies in Oslo
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
Income statement
NOK thousands
Item
2020
2021
2022
Revenue
0
0
4
Staff expenses
−0
−0
−0
EBITDA
0
−208
−303
Depreciation & amort.
−0
−0
−0
EBIT
0
−208
−303
Net financials
0
−1
0
Profit before tax
0
−209
−303
Tax
−0
−46
46
Net profit
0
−163
−349
Balance sheet
NOK thousands
Item
2020
2021
2022
Total assets
30
57
15
Equity
30
37
−204
Long-term debt
0
0
199
Short-term debt
0
20
20
Total debt
0
20
219
Financial ratios
5-year trend
EBITDA margin
-8245.8%
This company
15.8%
Market median
-52289% vs market
2020
2022
Equity ratio
-1405.7%
This company
38.2%
Market median
-3780% vs market
2020
2022
Return on equity
-34932500.0%
This company
18.4%
Market median
-189850643% vs market
2020
2022
Net profit margin
-9495.1%
This company
8.1%
Market median
-117323% vs market
2020
2022
Asset turnover
0.25×
This company
1.12×
Market median
-78% vs market
2020
2022
Debt / equity
1.07×
This company
0.62×
Market median
-73% vs market
2020
2022
Annual reports & filings
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
JM
Juan Martin Catelen
Chief Executive Officer
Chief Executive Officer
2020
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Luis Alejandro Miccio
Company
23.53%
23.53%
2023
Dolores Lozano Munoz
Individual
19.74%
19.74%
2023
Andrew James Buick
Individual
11.73%
11.73%
2023
Unknown
Individual
9.8%
9.8%
2022
Joaquin Luis Poggi
Individual
4.68%
4.68%
2023
William Buick Ltd
Company
4.21%
4.21%
2023
Analia Perez Simini
Company
2.45%
2.45%
2023
Maria Julia Catelen
Company
2.34%
2.34%
2023
Martin Geving Pedersen
Company
1.33%
1.33%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of GENE-USE.CO AS also hold positions in
0
other companies.
Person
Role here
Other companies
Juan Martin Catelen
Chief Executive Officer
0 companies